X

CAR-T Cell Therapy

CAR-T Cell Therapy

Newer Agents on the Horizon for Refractory or Relapsed DLBCL

Although treating patients with R/R DLBCL remains challenging, some newer therapies on the horizon offer promise including CAR T-cell therapy.

The ASCO Post
11/25/2021
B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma

Researchers generated B7-H3 targeted CAR-T-cells and tested their antitumor activities using patient derived tumor spheres.

Frontiers in Oncology
11/15/2021
FDA Grants Orphan Drug Designation to Dual-Target CAR-T for Advanced Multiple Myeloma

The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma.

Healio
11/19/2021

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma

Researchers examine the efficacy and safety of T cells containing a YYB-103 CAR that can preferentially bind to IL13Rα2 on MG cells.

Frontiers in Immunology
11/08/2021
TCR T-Cell Therapy Induces Response in Solid Cancers

Half of patients achieved objective response to an infusion of IMA203, an autologous TCR-T cell therapy that is gene-edited to express a T-cell receptor recognizing PRAME protein in tumor cells.

Healio
11/19/2021
Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell Malignancies

A modified version of the EASIX score, when calculated prior to and soon after CAR T-cell infusion, predicted severe CRS and ICANS before their occurrence. 

ASH Clinical News
11/01/2021
Contextual Reprogramming of CAR-T Cells for Treatment of HER2+ Cancers

RB-340-1 is presented as an all-in-one T cell product that couples anti-HER2 CAR signaling to CRISPRi-mediated PD-1 gene suppression to prolong CAR-T cell persistence, enhancing treatment outcomes.

Journal of Translational Medicine
11/07/2021
Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy

Researchers explore patient descriptions of key domains of health-related quality of life in DLBCL patients treated with CAR T therapy.

Oncology and Therapy
11/15/2021
Incidence and Risk Factors Associated With Bleeding and Thrombosis Following Chimeric Antigen Receptor T-Cell Therapy

Bleeding episodes and thrombotic complications and their associated clinical and laboratory characteristics were recorded in a cohort of 127 consecutive patients... 

Blood Advances
11/08/2021
Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy

Researchers find that the combination of EpCAM CAR T-cell therapy with the Wnt inhibitor can overcome the limitations of CAR T cells in treating solid tumors.

Frontiers in Pharmacology
11/01/2021
Tunable Control of CAR T Cell Activity Through Tetracycline Mediated Disruption of Protein–Protein Interaction

This work shows how optimization of split-CAR structure affects function and adds a novel design allowing easy CAR inhibition through an FDA-approved small molecule.

Scientific Reports
11/09/2021
CAR-T ‘Clearly Superior’ for Triple-Class Refractory Multiple Myeloma

Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options. 

Healio
11/12/2021
Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy

Researchers find that in contrast to T cells, the inclusion of NFκB-responsive elements within the inducible promoter construct was essential for CAR-inducible expression of the transgene.

Frontiers in Immunology
11/03/2021
Demethylating Therapy Increases Anti-CD123 CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia

Scientific findings indicate that AZA increases the immunogenicity of AML cells, enhancing recognition and elimination of malignant cells by highly efficient CTLA-4 - anti-CD123 CAR T cells.

Nature Communications
11/08/2021
Researchers Develop a New Class of CAR-T Cells That Target Previously Untargetable Cancer Drivers

Researchers were able to identify peptides that are presented on the surface of tumor cells and can be targeted with PC-CARs, a new class of engineered T cells, stimulating an immune response...

Science Daily
11/03/2021
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma

A novel CAR T-cell therapy targeting CD38 may be an effective option for multiple myeloma, according to research published in Frontiers in Oncology.

Hematology Advisor
11/04/2021
FDA Delays Decision on Ciltacabtagene Autoleucel CAR-T for Advanced Multiple Myeloma

The FDA has delayed its decision on a biologics license application for ciltacabtagene autoleucel, a CAR T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.

Healio
11/02/2021
Risk of Cytokine Release Syndrome After CAR T-Cell Therapy May Vary by Ethnicity

The risk of cytokine release syndrome after CAR T-cell therapy may vary by ethnicity and BMI, according to research presented at the 2021 AACR Conference on...

Cancer Therapy Advisor
10/15/2021
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Anti-CD19 CAR-T cells have demonstrated activity against relapsed/refractory lymphomas.

Frontiers in Immunology
10/12/2021
CAR T-Cell Therapies Show Similar Efficacy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A comparative analysis of the CAR T-cell therapies tisagenlecleucel and lisocabtagene maraleucel in patients with R/R DLBCL showed no significant differences in survival outcomes.

Cancer Therapy Advisor
09/11/2021
T Cell Receptor-Mimic CAR-T Cell Specific for a Kinetochore Protein Targets Multiple Hematological Malignancies

Researchers have successfully used a mass spectrometry-based approach to design a TCR-mimic CAR T-cell specific to the kinetochore protein NDC80 that targets multiple cancer cell lines.

Hematology Advisor
09/11/2021
Updated Safety and Efficacy of CAR-T Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

A single dose of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, yielded early, deep, and durable responses in heavily pre-treated patients with R/R MM.

Hematology Advisor
09/10/2021
Neuropsychiatric Disorders Common in Patients Who Receive CAR-T Therapy for Multiple Myeloma

More than one-quarter of patients who had CAR T-cell therapy for MM in 2018 had a neuropsychiatric disorder, according to results presented at the Annual SOHO Meeting.

Hematology Advisor
09/09/2021
Brentuximab Vedotin Plus CHP Provides Lasting Benefit in Peripheral T-Cell Lymphoma

The survival benefits seen with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone persist at 5 years, according to updated results from the ECHELON-2 trial.

Cancer Therapy Advisor
09/12/2021
Hematologic Malignancies Linked to Higher Risk of COVID-19 and Severe Outcomes

A new study supports prior findings that patients with hematologic malignancies have an increased risk of developing COVID-19 and having severe outcomes, which include ICU admission and COVID-relat

Cancer Therapy Advisor
09/09/2021

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834